Literature DB >> 32383342

Ultrafiltration volume by once-weekly hemodialysis is a predictor of technique survival of combination therapy with peritoneal dialysis and hemodialysis.

Mototsugu Tanaka1, Yoshitaka Ishibashi2, Yoshifumi Hamasaki1, Yuka Kamijo2, Mayumi Idei3, Takahiro Nishi4, Michio Takeda5, Hiroshi Nonaka6, Masaomi Nangaku1, Naobumi Mise7.   

Abstract

Overhydration is a major cause of technique failure of peritoneal dialysis (PD). Hence, we investigated the impact of ultrafiltration (UF) volume by once-weekly hemodialysis (HD), excess volume beyond their dry weight, on technique survival of PD and HD combination therapy (PD+HD). Forty-six anuric PD+HD patients were divided into three groups according to baseline UF volume by HD: low-UF (<mean - 1SD), middle-UF (≥mean - 1SD and <mean + 1SD), and high-UF (≥mean + 1SD). High-UF group showed larger extracellular water normalized to height (P = .038) and longer HD sessions (P < .001) compared with low-UF group, whereas low-UF group was older than middle-UF group (P = .001). Technique survival rate was significantly lower in high-UF group than in low and middle-UF groups (P < .001), and the rates at 44 months were 80%, 90%, 20% in low, middle, and high-UF groups, respectively. Chronic overhydration was the leading cause of technique failure for all. This study suggests that fluid overload remains a major cause of technique failure of PD even after once-weekly HD is added.
© 2020 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.

Entities:  

Keywords:  PD+HD; combined dialysis; end-stage renal disease; residual kidney function; technique failure

Year:  2020        PMID: 32383342     DOI: 10.1111/1744-9987.13509

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  1 in total

1.  Need for evidence on long-term prognosis of PD+HD: a commentary.

Authors:  Mototsugu Tanaka; Naobumi Mise
Journal:  BMC Nephrol       Date:  2021-01-07       Impact factor: 2.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.